Pharma News

As increased cases of monkeypox are being reported in the United States, the U.S. Biomedical Advanced Research and Development Authority (BARDA) has ordered an additional 500,000 additional doses o...

With the spread of monkeypox across the world coming hot on the heels of COVID-19, there are fears that increasing outbreaks of diseases that jump from animals to humans could spark another pandemi...

How do cancer cells differ from healthy cells?

The number of new coronavirus cases and deaths reported globally fell everywhere last week except the Middle East and Southeast Asia, according to the World Health Organization. ...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for BCX9250 for the prevention of heterotopic ossificati...

Researchers have uncovered a new function for alpha-synuclein, a well-known protein marker of Parkinson’s, with relevance toward treatment for the disease. ...

Abbott is already a big player in the wearable glucose-monitoring sector, and has started working on a new device that will measure both glucose and ketones, potentially serving as a warning system...

The UK medicines regulator has awarded Alnylam’s RNAi-based therapy zilebesiran for hypertension an ‘innovation passport‘, a designation designed to speed up NHS access to promising new medi...

Veru submitted an Emergency Use Authorization (EUA) application to the FDA for its investigational oral drug candidate sabizabulin for the treatment of moderate-to-severe hospitalized COVID-19 pati...

As Biogen continues to reel from the rollout (or lack thereof) of its FDA-approved Alzheimer’s med Aduhelm, the company is looking elsewhere for promising clinical candidates tackling neurodegen...

Patients with a particular kind of cancer and a particular kind of mutation received a new therapy called dostarlimab and had results not seen in a cancer trial before. ...

Praxis Precision Medicines’ investigational GABA type A receptor drug PRAX-114 failed a phase 2/3 clinical trial that was evaluating the drug’s efficacy and safety as monotherapy for patients w...